Differentiated Solutions for Long-term Resolution of Chronic Autoimmunity

A multinational biopharmaceutical company, with a long‑standing presence in rheumatology, immuno‑dermatology, bone disorders and neurological conditions, such as epilepsy, is now expanding their well-established activities in the immunology therapeutic area, with an ambition to bring transformational change to patients across priority disease indications focused on autoimmunity. This company is actively seeking approaches with potential for resolution and/or “reset” of the immune system with the potential to achieve long‑term disease and drug‑free remission...